EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine

Anastasia Bougea iD, Philippos Gourzis iD

Journal of Clinical Medicine · 08.08.2024 · 13 (16) · 4661

DOI: 10.3390/jcm13164661 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.08.2024. Verfasst von Anastasia Bougea und 1 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Neurology, National and Kapodistrian University of Athens, 15772 Athens, Greece. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Alzheimer’s disease (AD) is a worldwide neurodegenerative disorder characterized by the buildup of abnormal proteins in the central nervous system and cognitive decline. Since no radical therapy exists, only symptomatic treatments alleviate symptoms temporarily. In this review, we will explore the latest advancements in precision medicine and biomarkers for AD, including their potential to revolutionize the way we diagnose and treat this devastating condition. (2)

Methods

A literature search was performed combining the following Medical Subject Heading (MeSH) terms on PubMed: “Alzheimer’s disease”, “biomarkers”, “APOE”, “APP”, “GWAS”, “cerebrospinal fluid”, “polygenic risk score”, “Aβ42”, “τP-181”, “ p-tau217”, “ptau231”, “proteomics”, “total tau protein”, and “precision medicine” using Boolean operators. (3)

Results

Genome-wide association studies (GWAS) have identified numerous genetic variants associated with AD risk, while a transcriptomic analysis has revealed dysregulated gene expression patterns in the brains of individuals with AD. The proteomic and metabolomic profiling of biological fluids, such as blood, urine, and CSF, and neuroimaging biomarkers have also yielded potential biomarkers of AD that could be used for the early diagnosis and monitoring of disease progression. (4)

Conclusion

By leveraging a combination of the above biomarkers, novel ultrasensitive immunoassays, mass spectrometry methods, and metabolomics, researchers are making significant strides towards personalized healthcare for individuals with AD.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s disease (AD)biomarkersgenome-wide association studies (GWAS)precision medicine

Autor:innen und Institutionen

  • 1st Department of Neurology, National and Kapodistrian University of Athens, 15772 Athens, Greece.
  • 1st Department of Psychiatry, University of Patras, 26504 Rio, Greece.

ORCID-Profile: Anastasia Bougea, Philippos Gourzis

Zitieren

APA

Bougea, A., & Gourzis, P. (2024). Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine. Journal of Clinical Medicine, 13(16), 4661. https://doi.org/10.3390/jcm13164661

Vancouver

Bougea A, Gourzis P. Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine. Journal of Clinical Medicine. 2024;13(16):4661. doi:10.3390/jcm13164661

BibTeX
@article{Bougea2024,
  author = {Bougea, Anastasia and Gourzis, Philippos},
  title = {Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {16},
  pages = {4661},
  doi = {10.3390/jcm13164661}
}
Kostenlos starten →